Proprietary method in collaboration with Syncom B.V. will achieve a THC purity level of Greater than 95%
NEW YORK, Nov. 29, 2016 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc. (AXIM ® Biotech ) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods.
This invention relates to a method to extract THC-A from cannabis flower using a non-polar solvent, wherein the yield is approximately 50 - 70% with regards to THC-A content in the starting material. A neutral metal salt or inorganic base solution saturated with the metal neutral salt and adjusted to basic pH enables separation of the THC-A layer and significantly increases the yield. THC-A is decarboxylated in a water/ethanol solution to give THC at a purity higher than 95%.
The IP was generated in collaboration with Syncom B.V., a Netherlands-based leading company in custom synthesis solutions for pharmaceutical and biotech industry.
“We are pleased to announce the IP application of our own THC extraction method. There are many THC-based products on the market but none are pure grade. Our application, developed in conjunction with Syncom, is a game changer as the extraction method produces THC in the purest form. In addition, this new method will allow us to have the highest THC yields with no heavy metals, solvents or other unwanted residues,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “This new extraction application attests to the high competence of the AXIM research and development team, and will go a long way in supporting our mission in finding cannabinoid-derived solutions for health conditions with no known cure.”
CEO of Syncom, Dr. Ton Vries adds: “Syncom is glad to have made a relevant contribution to the novel extraction of THC, we will continue in collaborating with Axim and proceed with the development of state of the art active pharmaceutical Ingredients derived from the Cannabis plant”
About AXIM AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com .
About SYNCOM B.V. Syncom is a global leader in providing the pharmaceutical and biotech industries with custom synthesis solutions. Syncom has an excellent track record dating back to the foundation of the company in 1988. We count both leading global pharmaceutical companies as well as small virtual start up companies among our clients. In addition to our pharma activities we serve the diagnostic, fine chemical, electronic and pigment industries as well. For more information, visit www.syncom.nl FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE AXIM ® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 andrew.hard@cmwmedia.com www.cmwmedia.com Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
